4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate.

While this overall difference did not reach statistical significance, patients matched to post- versus pre-trial CONQUER subjects had significantly lower outpatient costs ($US16,901 vs. $US18,035; mean difference –1134, 95 % CI –2122 to –110; P = 0.03) and lower total prescription costs ($US7271 vs. $US8331; mean difference –1060; 95 % CI –1553 to –558; P < 0.001; Fig. 2 ).

also in 111,027 other papers